查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1987078

非黑色素瘤皮膚癌治療市場規模、佔有率、趨勢和預測：按治療方法、適應症、最終用途和地區分類，2026-2034 年

Non-Melanoma Skin Cancer Treatment Market Size, Share, Trends and Forecast by Treatment Type, Indication, End Use, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球非黑色素瘤皮膚癌治療市場規模為6.142億美元。展望未來，IMARC Group預測，該市場將以4.10%的複合年成長率成長，從2026年到2034年達到8.815億美元。目前，北美市場主導地位，預計2025年市佔率將達到42%。該地區受益於先進的醫療基礎設施、較高的皮膚癌診斷率、創新治療方法的廣泛應用、政府和私營機構的大力研發投入以及優惠的報銷政策，這些因素使得患者能夠獲得尖端治療。所有這些因素都促進了非黑色素瘤皮膚癌治療市場佔有率的成長。

全球非黑色素瘤皮膚癌（尤其是基底細胞癌和鱗狀細胞癌）發生率的上升是推動非黑色素瘤皮膚癌治療市場成長的主要因素。臭氧層損失導致紫外線照射增加、生活方式的改變（包括戶外活動增加）以及老年人口的成長（老年人更容易患皮膚惡性腫瘤）也促使人們對有效治療方法的需求不斷成長。放射治療技術的進步，例如近距離放射和強度調控放射治療（IMRT），正在提高治療的準確性和改善患者的預後。此外，動態療法的廣泛應用和新型免疫療法的開發也拓寬了治療選擇。醫療保健支出的成長、人們對皮膚癌早期檢測意識的提高以及政府主導的篩檢計畫也在促進市場成長。此外，人工智慧（AI）在診斷影像中的應用正在改善臨床決策和治療計劃。

美國之所以在非黑色素瘤皮膚癌治療市場佔據領先地位，原因有以下幾點：首先，由於紫外線照射強烈、人口老化以及人口以白皙膚色為主，美國擁有全球最高的皮膚癌發病率之一。其次，完善的醫療保健基礎設施、廣泛的醫療保險覆蓋範圍以及患者對皮膚癌篩檢的高度重視，都有助於早期診斷和治療。此外，強勁的研發活動也為非黑色素瘤皮膚癌治療市場的發展前景提供了支撐，領先的醫學研究機構正致力於開發新一代治療方法。第三，先進放射治療設備的普及、莫氏顯微外科手術的廣泛應用以及簡化的藥物核准流程，進一步鞏固了美國在非黑色素瘤皮膚癌治療市場的地位。最後，美國加強了公共衛生政策，鼓勵定期進行皮膚科檢查和做好防曬措施，從而提高了早期療育率。

非黑色素瘤皮膚癌治療市場趨勢：

擴大免疫療法的治療選擇

非黑色素瘤皮膚癌免疫療法的研發和監管核准的不斷推進，正在顯著改變該領域的治療格局。標靶PD-1通路免疫查核點抑制劑在治療進行性鱗狀細胞癌和基底細胞癌方面展現出卓越的療效，為患者提供了除傳統手術和放射治療之外的全新治療選擇。這些藥物透過恢復免疫系統識別和摧毀癌細胞的能力發揮作用，從而延長患者的無疾病生存期。例如，2025年10月，美國FDA核准了首個免疫療法藥物cemiplimab-rwlc，用於手術和放療後高風險皮膚鱗狀細胞癌的輔助治療，結果顯示該療法可降低疾病復發或死亡的風險。不斷擴充的聯合治療免疫療法研發管線及其作為新輔助療法的應用研究，進一步推動了非黑色素瘤皮膚癌治療市場的蓬勃發展。

放射治療技術的進步

放射線治療技術的顯著進步正在提高非黑色素瘤皮膚癌的治療精度和患者療效。現代放射治療治療方法，例如近距離放射、質子治療和容積調強放射治療（VMAT），使臨床醫生能夠在最大限度減少對周圍健康組織損傷的同時，精準地輸送靶向劑量。放射線治療已被證實對治療非黑色素瘤皮膚癌有效，尤其適用於不適合手術或腫瘤位於美容敏感部位的患者。例如，2025年發表在《放射腫瘤學進展》（Advances in Radiation Oncology）上的一項臨床研究報告稱，在單次門診治療中，使用錸治療185個病灶的完全緩解率達到94.1%。這些放射治療系統的創新正在顯著提升全球醫療機構對非黑色素瘤皮膚癌治療的需求，並推動市場發展趨勢。

早期發現和擴大篩檢

在全球範圍內，對皮膚癌早期檢測和篩檢計畫的日益重視正在推動治療需求並改善患者的治療效果。各國政府和醫療機構正透過宣傳宣傳活動、皮膚病篩檢計畫以及對數位醫療技術的投資，積極推廣非黑色素瘤皮膚癌的早期檢測。人工智慧（AI）影像系統和遠距皮膚病學平台等先進診斷工具，使得皮膚癌的檢測更加精準便捷，尤其是在醫療資源匱乏的地區。例如，根據GLOBOCAN 2022的數據，全球約有1,234,533人被診斷出患有非黑色素瘤皮膚癌，使其成為全球第五大常見癌症。如此沉重的疾病負擔迫使醫療系統加強早期療育策略並擴大治療基礎設施，為非黑色素瘤皮膚癌治療市場帶來持續成長的機會。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球非黑色素瘤皮膚癌治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依治療方法分類

  • 化療
  • 放射線治療
  • 動態療法
  • 其他

第7章 市場區隔：依應用領域分類

  • 基底細胞癌
  • T細胞淋巴瘤
  • 鱗狀細胞癌
  • 其他

第8章 市場區隔：依最終用途分類

  • 醫院
  • 專科診所
  • 門診手術中心
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Accuray Incorporated
    • Almirall SA
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Elekta AB
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Icad Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Sun Pharmaceutical Industries Limited
    • Varian Medical Systems Inc.
Product Code: SR112026A3438

The global non-melanoma skin cancer treatment market size was valued at USD 614.2 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 881.5 Million by 2034, exhibiting a CAGR of 4.10% from 2026-2034. North America currently dominates the market, holding a market share of 42% in 2025. The region benefits from advanced healthcare infrastructure, high skin cancer diagnosis rates, widespread adoption of innovative treatment modalities, strong research funding from government and private institutions, and favorable reimbursement policies that facilitate patient access to cutting-edge therapies, all contributing to the non-melanoma skin cancer treatment market share.

The increasing incidence of non-melanoma skin cancers worldwide, especially basal cell carcinoma and squamous cell carcinoma, is a major driving force for the growth of the non-melanoma skin cancer treatment market. The increasing exposure to ultraviolet radiation due to ozone layer depletion, as well as lifestyle changes that include increased outdoor exposure, and the growing geriatric population with increased susceptibility to skin malignancies are also contributing factors to the increasing demand for effective treatment options. Advances in radiation therapy technology, such as brachytherapy and intensity-modulated radiation therapy, are also improving the accuracy of treatment and patient outcomes. In addition, the increasing use of photodynamic therapy and the development of new immunotherapeutic agents are also expanding the treatment options. Increasing healthcare spending, increased awareness of early skin cancer detection, and government-sponsored screening programs are also fueling the growth of the market. The use of artificial intelligence in diagnostic imaging is also improving clinical decision-making and treatment planning.

The United States has turned out to be a prominent area in the non-melanoma skin cancer treatment market due to a number of reasons. The United States has one of the highest rates of skin cancer incidence in the world due to substantial exposure to ultraviolet radiation, an aging population, and a predominantly fair-skinned population. The well-developed healthcare infrastructure, widespread health insurance coverage, and high patient awareness regarding skin cancer screening have contributed to early diagnosis and treatment. In addition, the non-melanoma skin cancer treatment market outlook is aided by strong research and development, with the top academic medical institutions investing in the development of next-generation therapies. The presence of advanced radiation equipment, increasing use of Mohs micrographic surgery, and favorable approval processes for new drugs further enhance the position of the United States in the non-melanoma skin cancer treatment market. Furthermore, increased public health initiatives to encourage regular dermatological checks and sun protection measures are increasing early intervention rates in the United States.

NON-MELANOMA SKIN CANCER TREATMENT MARKET TRENDS:

Expanding Immunotherapy Treatment Options

The increasing development and regulatory approval of immunotherapeutic agents for non-melanoma skin cancers is significantly transforming the treatment landscape. Immune checkpoint inhibitors targeting the PD-1 pathway have demonstrated remarkable efficacy in managing advanced cutaneous squamous cell carcinoma and basal cell carcinoma, offering patients new therapeutic options beyond traditional surgery and radiation. These agents work by restoring the immune system's ability to recognize and destroy cancer cells, leading to improved disease-free survival outcomes. For instance, in October 2025, the US FDA approved cemiplimab-rwlc as the first immunotherapy for adjuvant treatment of high-risk cutaneous squamous cell carcinoma following surgery and radiation, demonstrating a reduction in the risk of disease recurrence or death. The growing pipeline of immunotherapy combinations and the exploration of neoadjuvant applications are further expanding the non-melanoma skin cancer treatment market forecast.

Advancing Radiation Therapy Technologies

Significant technological advancements in radiation therapy are enhancing treatment precision and patient outcomes in non-melanoma skin cancer management. Modern radiotherapeutic modalities, including brachytherapy, proton beam therapy, and volumetric modulated arc therapy, enable clinicians to deliver highly targeted doses while minimizing damage to surrounding healthy tissues. Radiation therapy has demonstrated efficacy in treating non-melanoma skin cancers and is particularly beneficial for patients who are not surgical candidates or have tumors in cosmetically sensitive areas. For instance, a 2025 clinical study published in Advances in Radiation Oncology reported that Rhenium-skin cancer therapy achieved a 94.1 percent complete response rate across 185 treated lesions in a single outpatient session. These innovations in radiation delivery systems are driving significant demand and supporting the non-melanoma skin cancer treatment market trends across global healthcare settings.

Rising Early Detection and Screening

The increasing emphasis on early detection and screening programs for skin cancer is driving treatment demand and improving patient outcomes worldwide. Governments and healthcare organizations are investing in public awareness campaigns, dermatological screening initiatives, and digital health technologies to facilitate earlier identification of non-melanoma skin cancers. Advanced diagnostic tools, including artificial intelligence-powered imaging systems and teledermatology platforms, are enabling more accurate and accessible skin cancer detection, particularly in underserved regions. For instance, according to the GLOBOCAN 2022 data, approximately 1,234,533 people were diagnosed with non-melanoma skin cancer globally, ranking it as the fifth most common cancer worldwide. This substantial disease burden is prompting healthcare systems to strengthen early intervention strategies and expand treatment infrastructure, thereby supporting sustained growth in the non-melanoma skin cancer treatment market growth opportunities.

NON-MELANOMA SKIN CANCER TREATMENT INDUSTRY SEGMENTATION:

Analysis by Treatment Type:

  • Chemotherapy
  • Radiation Therapy
  • Photodynamic Therapy
  • Others

Radiation therapy holds 39% of the market share. Radiation therapy is an important treatment option for non-melanoma skin cancers and provides effective tumor control for patients who are not ideal candidates for surgical treatment or have lesions in difficult anatomical sites. Radiation therapy includes different modalities such as external beam radiation, brachytherapy, and superficial radiation therapy, which are designed for specific tumor properties and patient needs. Radiation therapy is most commonly used for elderly patients and patients with multiple comorbidities, for whom the risk of surgery is high. The increasing use of advanced linear accelerators and advancements in image-guided treatment planning are further solidifying the leading market position of the segment. Moreover, advancements in adaptive radiotherapy and the development of precision-focused delivery systems are allowing radiation oncologists to deliver the maximum dose to the tumor while sparing the surrounding healthy tissues. The increasing development of outpatient radiation facilities and the increasing reimbursement support for non-invasive treatment modalities are further supporting the adoption of radiation therapy in different healthcare settings.

Analysis by Indication:

  • Basal Cell Carcinoma
  • T-Cell Lymphoma
  • Squamous Cell Carcinoma
  • Others

Basal cell carcinoma leads the market with a share of 65%. Basal cell carcinoma is the most common type of non-melanoma skin cancer, which originates from the basal cells of the epidermis and usually manifests as slowly growing and locally invasive neoplasms. The disease is a known consequence of cumulative exposure to ultraviolet radiation and is most common in fair-skinned populations in areas with high sun exposure. Current treatment modalities include surgical excision, Mohs micrographic surgery, radiation therapy, topical therapy, and hedgehog pathway inhibitors for advanced disease. The sheer dominance of basal cell carcinoma among all non-melanoma skin cancers translates to a huge demand for various treatment options. The dominance of this market segment is maintained by the increasing incidence rates, improved access to treatment, and increasing awareness about early skin examination practices. Moreover, recent developments in targeted therapies and the increasing use of minimally invasive techniques are expanding the treatment options. The expanding geriatric population with heightened susceptibility to cumulative sun damage and the improvement of diagnostic capabilities in primary care settings are further reinforcing the leading position of this segment.

Analysis by End Use:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgery Centers
  • Others

Hospitals dominate the market, with a share of 49%. Hospitals are the main treatment centers for non-melanoma skin cancer, thanks to their comprehensive infrastructure, multidisciplinary staff, and availability of advanced treatment technologies. The hospitals provide a complete range of treatment modalities, including surgical procedures, radiation therapy facilities, photodynamic therapy stations, and systemic therapy administration. The hospitals are especially important for the treatment of complex and advanced cases that require a multidisciplinary approach involving specialties such as dermatology, oncology, pathology, and plastic surgery. The availability of advanced diagnostic equipment, imaging facilities, and inpatient services makes hospitals the preferred treatment centers for comprehensive skin cancer care. Furthermore, the increasing use of electronic health records and clinical decision support systems in hospital settings is improving treatment standardization and patient management. The rising trend of setting up skin cancer units in hospital oncology divisions and the expansion of outpatient treatment services in hospitals are further solidifying the dominance of this market segment in the overall market dynamics.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market with a 42% market share. The dominance of the region is fueled by the high prevalence of non-melanoma skin cancer among the predominantly fair-skinned population, along with the advanced healthcare infrastructure and research capabilities. North America enjoys the presence of large pharmaceutical and medical device companies that are constantly working on the development of innovative treatment options, well-structured reimbursement systems that make it easy for patients to access treatments, and generous government support for cancer research. In addition, the region's widespread presence of specialized cancer care facilities and high awareness levels about skin cancer screening are also responsible for early detection and comprehensive treatment of patients. The presence of advanced radiation therapy equipment, widespread use of Mohs micrographic surgery, and increasing use of immunotherapeutic agents are also enhancing the treatment environment in the region. In addition, the supportive regulatory framework that promotes expedited approval routes for new cancer therapies and the increasing use of digital health technologies in dermatology are also solidifying North America's position as a leader in the global non-melanoma skin cancer treatment market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES NON-MELANOMA SKIN CANCER TREATMENT MARKET ANALYSIS

The United States is the largest and most impactful market for non-melanoma skin cancer treatment in North America, due to the presence of an exceptionally high prevalence rate of the disease, an advanced medical infrastructure, and a strong focus on innovation in cancer treatment. The United States has a well-structured healthcare system that offers access to a broad range of skin cancer treatments, including surgical excision, Mohs micrographic surgery, radiation therapy, photodynamic therapy, and promising immunotherapies. The country's healthcare system has extensive health insurance coverage that makes it possible for patients to access both established and emerging therapies. The presence of top-class academic medical institutions and cancer research organizations in the United States fuels ongoing innovation in treatment approaches. Moreover, the country's FDA has favorable procedures for fast-track approval of new drugs, an increasing focus on personalized medicine, and public awareness campaigns regarding skin cancer prevention and early diagnosis, which further consolidate the United States market and expedite the adoption of therapies across the healthcare spectrum.

EUROPE NON-MELANOMA SKIN CANCER TREATMENT MARKET ANALYSIS

Europe represents a significant market for non-melanoma skin cancer treatment, supported by well-developed healthcare systems, universal health coverage in many countries, and growing awareness about skin cancer prevention and screening. The region faces a rising skin cancer burden, driven by aging populations, historical outdoor lifestyle patterns, and cumulative ultraviolet radiation exposure among predominantly fair-skinned populations. European countries, particularly Germany, the United Kingdom, France, and Italy, maintain advanced oncology infrastructure with specialized dermatology centers and comprehensive treatment capabilities. For instance, according to an industry report, non-melanoma skin cancers in Europe are projected to increase in incidence by approximately 40 percent by 2040, with associated mortality rising by around 50 percent. The European Medicines Agency's proactive regulatory framework and growing emphasis on immunotherapy approvals, including the recent positive opinion for cemiplimab as adjuvant treatment for high-risk cutaneous squamous cell carcinoma, are further expanding treatment options and market potential across the region.

ASIA-PACIFIC NON-MELANOMA SKIN CANCER TREATMENT MARKET ANALYSIS

The Asia-Pacific region is emerging as a significant growth market for non-melanoma skin cancer treatment, driven by rising skin cancer incidence, improving healthcare infrastructure, and increasing awareness about early detection and treatment. Countries such as Australia, Japan, South Korea, and China are leading regional market development through expanding oncology facilities and growing adoption of advanced treatment technologies. For instance, according to the Global Burden of Disease Study, East Asia experienced the highest growth rate in skin cancer incidence globally from 1990 to 2021, with an estimated annual percentage change of 4.42 percent. The region's expanding dermatology workforce, increasing government investment in cancer care programs, and growing access to radiation therapy and immunotherapy are driving sustained market expansion.

LATIN AMERICA NON-MELANOMA SKIN CANCER TREATMENT MARKET ANALYSIS

Latin America is witnessing growing demand for non-melanoma skin cancer treatment, supported by increasing disease awareness, expanding healthcare infrastructure, and rising healthcare expenditure across the region. Brazil and Mexico represent the largest markets, benefiting from improving access to oncology services and growing investment in advanced treatment technologies. The incidence of non-melanoma skin cancers in Latin America continues to rise, driven by high ultraviolet radiation exposure in tropical and subtropical zones. Government-led screening initiatives and expanding public health programs are enhancing early detection and treatment uptake throughout the region.

MIDDLE EAST AND AFRICA NON-MELANOMA SKIN CANCER TREATMENT MARKET ANALYSIS

The Middle East and Africa region is gradually expanding its non-melanoma skin cancer treatment market, driven by increasing awareness, improving diagnostic capabilities, and growing healthcare infrastructure. While skin cancer incidence rates in the region are relatively lower compared to North America and Europe, rising ultraviolet exposure and population growth are contributing to increasing case numbers. According to a study on global skin cancer patterns, despite relatively lower incidence rates in Africa, non-melanoma skin cancer mortality rates remain notable due to delayed diagnosis and limited treatment access. Ongoing investments in healthcare modernization and the establishment of specialized oncology centers are expected to support market growth.

COMPETITIVE LANDSCAPE:

The competitive environment of the global non-melanoma skin cancer treatment market is marked by the involvement of prominent pharmaceutical companies, medical device manufacturers, and biotech companies in the development and commercialization of innovative treatment options. Major players in the market are making efforts to enhance their oncology pipelines through strategic acquisitions, licensing agreements, and research collaborations to improve treatment outcomes. Substantial investments are being made by companies in clinical trials of new immunotherapies, targeted therapies, and advanced radiation therapy platforms to meet the unmet medical needs of patients. The approval of cemiplimab as adjuvant immunotherapy has significantly changed treatment practices, and this has increased competition among companies developing PD-1 inhibitors. Moreover, companies are also making efforts to increase their presence in the global market through collaborations with local distributors and healthcare organizations, especially in emerging markets with rising demand for advanced skin cancer treatment options.

The report provides a comprehensive analysis of the competitive landscape in the non-melanoma skin cancer treatment market with detailed profiles of all major companies, including:

  • Accuray Incorporated
  • Almirall S.A.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Elekta AB
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Icad Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Sun Pharmaceutical Industries Limited
  • Varian Medical Systems Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the non-melanoma skin cancer treatment market?

2. What is the future outlook of non-melanoma skin cancer treatment market?

3. What are the key factors driving the non-melanoma skin cancer treatment market?

4. Which region accounts for the largest non-melanoma skin cancer treatment market share?

5. Which are the leading companies in the global non-melanoma skin cancer treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Melanoma Skin Cancer Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Chemotherapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Radiation Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Photodynamic Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Basal Cell Carcinoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 T-Cell Lymphoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Squamous Cell Carcinoma
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Accuray Incorporated
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Almirall S.A.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Elekta AB
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Eli Lilly and Company
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 F. Hoffmann-La Roche AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 SWOT Analysis
    • 14.3.8 Icad Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Merck & Co. Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sun Pharmaceutical Industries Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Varian Medical Systems Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Non-Melanoma Skin Cancer Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Treatment Type (in %), 2025
  • Figure 4: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Indication (in %), 2025
  • Figure 5: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by End Use (in %), 2025
  • Figure 6: Global: Non-Melanoma Skin Cancer Treatment Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 8: Global: Non-Melanoma Skin Cancer Treatment (Chemotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Non-Melanoma Skin Cancer Treatment (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Non-Melanoma Skin Cancer Treatment (Radiation Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Non-Melanoma Skin Cancer Treatment (Radiation Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Non-Melanoma Skin Cancer Treatment (Photodynamic Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Non-Melanoma Skin Cancer Treatment (Photodynamic Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Non-Melanoma Skin Cancer Treatment (Other Treatment Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Non-Melanoma Skin Cancer Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Non-Melanoma Skin Cancer Treatment (Basal Cell Carcinoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Non-Melanoma Skin Cancer Treatment (Basal Cell Carcinoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Non-Melanoma Skin Cancer Treatment (T-Cell Lymphoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Non-Melanoma Skin Cancer Treatment (T-Cell Lymphoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Non-Melanoma Skin Cancer Treatment (Squamous Cell Carcinoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Non-Melanoma Skin Cancer Treatment (Squamous Cell Carcinoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Non-Melanoma Skin Cancer Treatment (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Non-Melanoma Skin Cancer Treatment (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Non-Melanoma Skin Cancer Treatment (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Non-Melanoma Skin Cancer Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Non-Melanoma Skin Cancer Treatment (Specialty Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Non-Melanoma Skin Cancer Treatment (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Non-Melanoma Skin Cancer Treatment (Ambulatory Surgery Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Non-Melanoma Skin Cancer Treatment (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Non-Melanoma Skin Cancer Treatment (Other End Uses) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Non-Melanoma Skin Cancer Treatment (Other End Uses) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: North America: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: North America: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: United States: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: United States: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Canada: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Canada: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Asia Pacific: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Asia Pacific: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: China: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: China: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Japan: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Japan: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: India: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: India: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: South Korea: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: South Korea: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Australia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Australia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Indonesia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Indonesia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Europe: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Europe: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Germany: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Germany: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: France: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: France: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: United Kingdom: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: United Kingdom: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Italy: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Italy: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Spain: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Spain: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Russia: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Russia: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Latin America: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Latin America: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Brazil: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Brazil: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Mexico: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Mexico: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market: Breakup by Country (in %), 2025
  • Figure 80: Middle East and Africa: Non-Melanoma Skin Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Global: Non-Melanoma Skin Cancer Treatment Industry: SWOT Analysis
  • Figure 82: Global: Non-Melanoma Skin Cancer Treatment Industry: Value Chain Analysis
  • Figure 83: Global: Non-Melanoma Skin Cancer Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Melanoma Skin Cancer Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 3: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 4: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by End Use (in Million USD), 2026-2034
  • Table 5: Global: Non-Melanoma Skin Cancer Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Non-Melanoma Skin Cancer Treatment Market Structure
  • Table 7: Global: Non-Melanoma Skin Cancer Treatment Market: Key Players